肺癌患者血清中VEGF,TIMP-1和MMP-9水平变化及临床意义

目的:研究肺癌患者血清中血管内皮生长因子(VEGF)、组织金属蛋白酶抑制剂1(TIMP-1)、基质金属蛋白酶9(MMP-9)水平变化及临床意义。方法:选取2014年3月至2016年3月来我院治疗的91例肺癌患者为病例组,同期选取40例健康者为对照组,酶联免疫吸附测定法(ELISA)测定两组血清VEGF、TIMP-1、MMP-9水平,分析肺癌患者上述指标与病理特征的关系,并采用spearman检验分析相关性。结果:病例组血清VEGF、TIMP-1、MMP-9水平均高于对照组,差异均具有统计学意义(P0.05)。肺癌患者血清VEGF、TIMP-1、MMP-9水平均与肿瘤体积大小、TNM分期、淋巴结转移、远处转移有关(P0.05)。肺癌患者血清MMP-9与TIMP-1正相关(r=0.337,P0.05)、血清MMP-9与VEGF正相关(r=0.312,P0.05)、血清TIMP-1与VEGF正相关(r=0.316,P0.05)。结论:血清VEGF、TIMP-1、MMP-9相互作用、协同参与肺癌的发生及侵袭转移,可作为肺癌诊断及预后评估的生物学标志物。

Changes of the Levels of Serum VEGF, TIMP-1 and MMP-9 in Patients with Lung Cancer and its Clinical Significance

ABSTRACT Objective: To study the changes of the levels of serum vascular endothelial growth factor(VEGF), tissue inhibitor of metalloproteinases-1(TIMP-1) and matrix metalloprotein-9(MMP-9)in patients with lung cancer and its clinical significance. Methods: 91 cases of patients with lung cancer were selected as the case group treated in our hospital from March 2014 to March 2016, and selected 40 healthy people as the control group in the same period, used enzyme linked immunosorbent assay(ELISA) to detect the levels of serum VEGF, TIMP-1, MMP-9 in two groups, then analyzed the relationship between the above indexes and pathological characteristics of patients with lung cancer, and the correlation was analyzed by Spearman test. Results: The levels of serum VEGF, MMP-9, TIMP-1 in case group were higher than control group respectively, the differences were statistically significant(P<0.05). The levels of serum VEGF, MMP-9 and TIMP-1 were related to the tumor volume, TNM stage, lymph node metastasis and distant metastasis in patients with lung cancer. Serum MMP-9 correlated with TIMP-1(r=0.337, P<0.05), serum MMP-9 correlated with VEGF(r=0.312, P<0.05), and serum TIMP-1 correlated with VEGF(r=0.316, P<0.05) in patients with lung cancer. Conclusion: Serum VEGF, TIMP-1, MMP-9 are interaction and co participation in the occurrence, invasion and metastasis of lung cancer, which are available as biological markers on diagnosis and prognosis assessment of lung cancer.